Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • HS-110
    • HS-130
    • Expanded Access
    • Scientific Publications
  • Investors
  • News & Media
  • Careers
  • Contact

News Releases

Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

Apr 18, 2019

Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019

Apr 2, 2019

Heat Biologics Reports 2018 Results and Provides Corporate Update

Mar 28, 2019

Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy

Mar 21, 2019

Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai

Mar 5, 2019

Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium

Feb 28, 2019

UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial

Jan 14, 2019

Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial

Jan 14, 2019

Heat Biologics Provides Clinical and Business Update

Jan 10, 2019

Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Jan 8, 2019
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...29
    NightHawk Biosciences

    OUR ECOSYSTEM

    SkunkWorx Bio
    Heat Biologics
    Elusys Therapeutics Inc.
    Pelican Therapeutics
    Scorpion Biological Services
    © 2022 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn